Siyuan Li

Anesthesia & Comfort Medical Center, Xi'an International Medical Center Hospital, Xi'an, Shaanxi, China.

2 papers in the library · 8 citations · publishing 2025-2026

Papers

The effect of low-dose esketamine on maternal depression after cesarean delivery.

Journal of psychosomatic obstetrics and gynaecology December 1, 2025 Yan Shang, Siyuan Li, Qin Zheng et al. 8 citations

Low-dose intravenous esketamine given during and after cesarean section reduces postpartum depression scores. In a randomized, double-blind, placebo-controlled trial of 186 women aged 20-50 years, those receiving esketamine (either intraoperatively alone or combined with patient-controlled intravenous analgesia) showed greater reductions in Edinburgh Postnatal Depression Scale scores at 5, 7, and 14 days after surgery compared to placebo. Sleep quality, pain scores, and analgesic use did not differ between groups. Mild, temporary side effects were more frequent with combined esketamine and PCIA. The findings suggest esketamine is a safe and effective approach for lowering postpartum depression risk after cesarean delivery.

DOI: 10.1080/0167482X.2025.2527659 Full text Esketamine Epds Cesarean section Patient-controlled intravenous analgesia +3

Effective doses of esketamine oral or esketamine intranasal for the prevention of preoperative anxiety in pediatric patients: A randomized double-blind dose-finding trial

Medicine March 6, 2026 Hongfei Xiong, Yingxue Xu, Jiayi Liu et al.

Single-dose esketamine, given orally or intranasally, effectively reduces preoperative anxiety in children. The 95% effective dose (ED95) for oral administration is 8.2125 mg/kg (95% CI: 7.4250-8.4597 mg/kg), and for intranasal administration is 2.1770 mg/kg (95% CI: 2.0952-2.1958 mg/kg). The findings indicate both safety and efficacy for this use.

DOI: 10.1097/md.0000000000048048 Anxiety Ketamine Medicine Nasal administration +4